While the CD95/Fas ligand and TNF-α appear as problematic for systemic treatment due to severe side effects, such as liver toxicity and induced inflammation, TRAIL has been shown to induce apoptosis in several cancers, while normal cells are largely protected [61,62,63]. The gene discussed is TNFSF10; the disease is cancer.